Company intelligence / Profile preview

HeadSense Medical

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

The HS‑1000 device was clinically validated in multiple trials worldwide for non-invasive intracranial pressure monitoring. It received CE approval and demonstrated potential to safely and accurately monitor brain physiological parameters with minimal discomfort. Clinical studies included stroke diagnosis/monitoring and comparison to invasive ICP methods. The company has since been dissolved.

Therapeutic areas: OncologyNeurology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

GE VenturesPontifax Venture Capital FundEverett PartnersJuMaJo GmbH

Beyond the preview

Go deeper on HeadSense Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HeadSense Medical.

Explore the full profile